

Technology Advisory Committee D Interests Register

Topic: Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]

Publication Date: 20/11/2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Will Sullivan	Committee member	Direct - Financial	<p>Through work at his past employer, Dr Sullivan provided advice and support to Merck Sharp & Dohme regarding pembrolizumab for peri-adjuvant non-small-cell lung cancer. This engagement ended in October 2023. Through work at his past employer, Will also provided advice and support to the same company regarding pembrolizumab for locally advanced, unresectable esophagael/gastroesophagael junction cancer. This engagement ended on 6 November 2023, when Will's employment at Delta Hat ended.</p> <p>No comparator company conflicts to declare for the past 12 months.</p>	10/07/2024	It was agreed that Dr Sullivan's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Matthew Bradley	Committee Member	Direct – Financial	Dr Bradley holds shares in the company AstraZeneca.	11/07/2024	It was agreed that Dr Bradley's declaration would prevent him from participating in discussions on this appraisal.
Dr Riyaz Shah	Committee Member	Direct - Financial	<p>Dr Shah is a full time NHS consultant, Private oncologist, and medicolegal advisor</p> <p>Dr Shah has receive, Advisory/speaker/conference support from Boehringer Ingelheim, AstraZeneca, Roche, BMS, MSD, Pfizer, Lilly, Novartis, Takeda, Bayer, BeiGene, Guardant, Sanofi</p>	11/01/2024	It was agreed that Dr Shah's declaration would not prevent him from providing expert advice to the committee.
Dr Toby Talbot	Clinical Expert	Direct - Financial	<p>Dr Talbot has participated in advisory board activity with MSD and speaker fees for the following engagements:</p> <ul style="list-style-type: none"> Clinical expert at MSD UK NSCLC advisory board held on 1st December 2023 	29/01/2024	It was agreed that Dr Talbot's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> • Speaker at MSD symposium at BTOG annual meeting held on 26th April 2023 		
Dr Yvonne Summers	Clinical Expert	Direct - Financial	Participated in an advisory boards with AstraZeneca, Amgen, Roche, Jansen and Jansen, Lilly, and MSD within the past 12 months.	29/01/2024	It was agreed that Dr Summers' declaration would not prevent her from providing expert advice to the committee.